Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 3
Submit an article Journal homepage
3,186
Views
5
CrossRef citations to date
0
Altmetric
Articles

Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials

Alice B. Gottlieba Icahn School of Medicine at Mount Sinai, New York, NY, USACorrespondence[email protected]
View further author information
,
Jashin J. Wub Dermatology Research and Education Foundation, Irvine, CA, USAView further author information
,
Christopher E. M. Griffithsc Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester, Manchester, UKView further author information
,
Kwaku Marfod Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Elisa Muscianisie Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
,
Xiangyi Menge Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAView further author information
,
Jennifer Fruehd Novartis Pharma AG, Basel, SwitzerlandView further author information
&
Mark Lebwohla Icahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
 show all
Pages 1482-1490 | Received 27 Aug 2020, Accepted 23 Sep 2020, Published online: 21 Oct 2020

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Marco Galluzzo, Marina Talamonti, Nicoletta Bernardini, Andrea Chiricozzi, Clara De Simone, Claudio Bonifati, Pierluigi Bruni, Federico Diotallevi, Maria Esposito, Dario Graceffa, Katharina Hansel, Francesco Loconsole, Gaia Moretta, Cristina Mugheddu, Manuela Papini, Antonio Richetta, Nevena Skroza, Laura Atzori, Maria Concetta Fargnoli, Severino Persechino, Annamaria Offidani, Luca Stingeni, Ketty Peris, Concetta Potenza & Luca Bianchi. (2022) Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. Expert Opinion on Biological Therapy 22:12, pages 1585-1592.
Read now

Articles from other publishers (4)

Ruby S. Gibson, Prerna Salian, Ashley Beckles, Robert Stavert, Steven Tahan, Alexa B. Kimball & Martina L. Porter. (2023) Treatment of necrobiosis lipoidica with secukinumab (Cosentyx): a case series. International Journal of Dermatology 62:9, pages 1198-1201.
Crossref
Elena Campione, Sara Lambiase, Ruslana Gaeta Shumak, Marco Galluzzo, Caterina Lanna, Gaetana Costanza, Cristiana Borselli, Fabio Artosi, Terenzio Cosio, Lorenzo Tofani, Annunziata Dattola, Francesca Di Daniele & Luca Bianchi. (2023) A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients. Pharmaceuticals 16:4, pages 526.
Crossref
Peter Foley, Tsen-Fang Tsai, Karl Rodins, Issam Ribhi Hamadah, Alfred Ammoury, Hussein Abdel Dayem, Mahmoud Abdallah, Susanne Crowe, Silvia Haas, Effie Pournara, Piotr Jagiello & Yu-Huei Huang. (2022) Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study. Dermatology and Therapy 12:2, pages 511-527.
Crossref
Giovanni Damiani, Giulia Odorici, Alessia Pacifico, Aldo Morrone, Rosalynn R. Z. Conic, Tima Davidson, Abdulla Watad, Paolo D. M. Pigatto, Delia Colombo, Piergiorgio Malagoli & Marco Fiore. (2022) Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching. Pharmaceuticals 15:1, pages 95.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.